Georgiamune sells solid tumor drug to Italy's Menarini for up to $1.1B
A small Maryland biotech is shipping a preclinical cancer drug to a family-owned Italian pharma in a deal worth up to $1.1 billion if all goes according to plan, the companies exclusively told Endpoints News. ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.